Brainstorm Cell Therapeutics (NASDAQ:BCLI) Releases Earnings Results, Misses Expectations By $0.02 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), MarketWatch Earnings reports. During the same quarter last year, the business posted ($0.19) earnings per share.

NASDAQ:BCLI opened at $2.95 on Wednesday. The stock’s 50-day simple moving average is $3.17 and its 200 day simple moving average is $3.27. Brainstorm Cell Therapeutics has a twelve month low of $2.65 and a twelve month high of $4.46.

Separately, StockNews.com started coverage on Brainstorm Cell Therapeutics in a report on Saturday. They issued a “hold” rating for the company.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Brainstorm Cell Therapeutics by 0.7% in the fourth quarter. BlackRock Inc. now owns 472,476 shares of the biotechnology company’s stock valued at $1,890,000 after buying an additional 3,509 shares during the period. Wells Fargo & Company MN grew its stake in shares of Brainstorm Cell Therapeutics by 40.8% during the 4th quarter. Wells Fargo & Company MN now owns 18,558 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 5,376 shares during the period. State Street Corp lifted its holdings in Brainstorm Cell Therapeutics by 10.8% during the 1st quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 9,357 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Brainstorm Cell Therapeutics by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 275,750 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 10,612 shares during the last quarter. Finally, Morgan Stanley grew its position in Brainstorm Cell Therapeutics by 42.3% during the 2nd quarter. Morgan Stanley now owns 53,685 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 15,964 shares during the last quarter. 12.28% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics (Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

See Also

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.